RCS - Theracryf PLC - Marking Addiction Awareness Week

TheracryfAnnouncement

26/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251126:nRSZ9950Ia&default-theme=true

RNS Number : 9950I  Theracryf PLC  26 November 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Marking Addiction Awareness Week 2025

 

Alderley Park, 26 November 2025 - TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on brain disorders, is supporting
Addiction Awareness Week.

23-30 November is the UK's national Addiction Awareness Week 2025, aiming to
raise awareness of the challenges and stigma around addiction.

Addictions, particularly Substance Use Disorders, are a chronic, relapsing
group of disorders with a high unmet medical need.  The number of people
affected is astonishing, with up to 2.2% of the global population estimated to
have a Substance Use Disorder 1 . Current treatments often see high relapse
rates, and there are limited long-term pharmacological options.

Last year in the UK, addiction was the cause of more deaths than road traffic
collisions, and it costs the economy more than £21bn per year. Alcohol
addiction alone costs the NHS more than £3.5bn per year.

TheraCryf is honoured to be contributing to the potential treatment of
addiction with its lead Ox-1 orexin -1 blocker programme, targeting binge
eating disorder and other substance use disorders.

As noted earlier this month, the programme is progressing on budget and ahead
of schedule, with the 0.5kg scale-up completed ahead of schedule,
manufacturing of 2kg human grade material initiated and the scale-up to 10kg
manufacturing proceeding to plan. This is with our aim of achieving clinic
readiness by the end of 2026.

TheraCryf has also has robust patent protection for Ox-1, with the recent
patent grant in Korea, complementing long lasting patent protection in all
major territories including Europe and USA.

Dr Huw Jones, CEO of TheraCryf, said:

"In marking Addiction Awareness Week, we are conscious of the very real unmet
medical need in addiction. Addictive disorders affecting hundreds of millions
of people and their families across the world, with the global cost burden
running into many tens of billions. We are focused on helping to reduce both
the human and financial costs of these conditions and getting our promising
Ox-1 programme into the clinic as soon as possible."

-Ends-

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris/ Melanie Toyne Sewell                   theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 1  - Castaldelli-Maia, JM et al (2022), 'Analysis of global prevalence of
mental and substance use disorders within countries: focus on sociodemographic
characteristics and income levels', International Review of Psychiatry,
Feb;34(1): pp6-15

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALELLLEFLBFBX



            Copyright 2019 Regulatory News Service, all rights reserved